New study reveals why patients stop taking GLP-1 obesity drugs
Share this
Recent posts
-
CDC study links later clinic visits to lower antihypertensive adherence
-
Predicting early-onset colorectal cancer with large language models
-
GLP-1 RA prescription trends: January 2019 – March 2026
-
AMCP 2026: Impact of the CVS GLP-1 formulary change
-
AMCP 2026: Real-world adherence and MRI monitoring patterns among patients treated with lecanemab in the United States
Follow Truveta
Stay up-to-date